News archive

Soka University Soka University
Ritsumeikan University Ritsumeikan University
Kindai University Kindai University
Epithelial cancer cells

Developed a highly sensitive measurement system for diagnosis of high-risk prostate cancer. Enabling highly effective and rapid detection of cancer while reducing the burden on patients -- Kindai University

- Measures serum core-type fucosylated PSA, which was not possible in the past, with high speed and high sensitivity - Verified that fucosylated PSA index significantly rises in a man with high-risk prostate cancer - Adjunct in the conventional PSA test, high-risk prostate cancer can be effectively detected

Preclinical Stage Verification for Combined Use of a Drug Under Development with an Existing Drug to Stimulate the Immune System to Attack Cancer Cells - Kindai University

Preclinical Stage Verification for Combined Use of a Drug Under Development with an Existing Drug to Stimulate the Immune System to Attack Cancer Cells - Kindai University

The research team from Kindai University's Faculty of Medicine, in cooperation with DAIICHI SANKYO COMPANY, LIMITED, have verified at the preclinical stage that using the currently under-development anti-cancer drug, U3-1402*1, in combination with immune checkpoint inhibitors*2 has the potential to be an effective treatment.

Ground Breaking Development of World’s First CurativeTreatment of Intractable Hepatocellular Carcinoma Path to Establishment of Standard Treatment of Hepatocellular Carcinoma - Kindai University

Senior Administrator Masatoshi Kudo of Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology, with his research group has invented a new method (LEN-TACE) of treating patients with intractable multinodular or large liver cancers, particularly those with near advanced liver cancer.